Literature DB >> 17350302

Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature.

Jaime Guevara-Aguirre1, Arlan L Rosenbloom, Marco Guevara-Aguirre, Kemal Yariz, Jeanette Saavedra, Lisa Baumbach, Jonathan Shuster.   

Abstract

CONTEXT &
OBJECTIVE: The Ecuadorian GH receptor deficiency (GHRD)/Laron syndrome population is the only large cohort with a single GHR mutation (E180 splice), permitting identification of numerous carrier and noncarrier first-degree relatives, to ascertain effects of heterozygosity on GH-dependent IGF-I and IGFBP-3 concentrations and on growth.
DESIGN: First-degree relatives (n=212) of GHRD patients had specimens taken for IGF-I, IGFBP-3, and GHR genotyping. Normal statured (n=40) and short statured (n=40) unrelated controls had measurement of IGF-I, IGFBP-3, and stature.
RESULTS: There were no significant differences between heterozygous and homozygous normal relatives in IGF-I or IGFBP-3 standard deviation scores (SDS). Heterozygous relatives had lower mean height SDS than did homozygous normals, but with extensive overlap between genotype groups in both child and adult relatives. Height SDS in general did not relate to IGF-I or IGFBP-3 concentrations.
CONCLUSIONS: GH-dependent IGF-I and IGFBP-3 secretion is not affected by heterozygosity for the E180 splice mutation that causes GHRD/Laron syndrome in the Ecuadorian population. Heterozygosity is associated with reduction in mean statural SDS, but this is not sufficient to be clinically important and not mediated through measurable differences in circulating IGF-I or IGFBP-3 related to genotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350302     DOI: 10.1016/j.ghir.2007.01.016

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  6 in total

Review 1.  Genetic evaluation of short stature.

Authors:  Andrew Dauber; Ron G Rosenfeld; Joel N Hirschhorn
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958

Review 2.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Toward gene therapy of Laron syndrome.

Authors:  Haim Werner
Journal:  Gene Ther       Date:  2022-03-14       Impact factor: 4.184

4.  Towards identification of molecular mechanisms of short stature.

Authors:  Lindsey A Waldman; Dennis J Chia
Journal:  Int J Pediatr Endocrinol       Date:  2013-11-20

5.  Height-reducing variants and selection for short stature in Sardinia.

Authors:  Magdalena Zoledziewska; Carlo Sidore; Charleston W K Chiang; Serena Sanna; Antonella Mulas; Maristella Steri; Fabio Busonero; Joseph H Marcus; Michele Marongiu; Andrea Maschio; Diego Ortega Del Vecchyo; Matteo Floris; Antonella Meloni; Alessandro Delitala; Maria Pina Concas; Federico Murgia; Ginevra Biino; Simona Vaccargiu; Ramaiah Nagaraja; Kirk E Lohmueller; Nicholas J Timpson; Nicole Soranzo; Ioanna Tachmazidou; George Dedoussis; Eleftheria Zeggini; Sergio Uzzau; Chris Jones; Robert Lyons; Andrea Angius; Gonçalo R Abecasis; John Novembre; David Schlessinger; Francesco Cucca
Journal:  Nat Genet       Date:  2015-09-14       Impact factor: 38.330

6.  GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6Ψ) patients.

Authors:  Sumana Chatterjee; Emily Cottrell; Stephen J Rose; Talat Mushtaq; Avinash Vickram Maharaj; Jack Williams; Martin O Savage; Louise A Metherell; Hl Storr
Journal:  Endocr Connect       Date:  2020-02-01       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.